Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
(NASDAQ:PRAX), BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 2,212,000 shares of its common stock at a […]